Global Xerostomia Treatments Market Overview:
Xerostomia is a condition that leads to the dry mouth caused by the minimal amount or absence of saliva in the mouth. Xerostomia is not viewed as a disease, but rather as a symptom. Xerostomia can be caused by radiation to the head or neck, or as a side effect of medications. In addition to the underlying disease as the cause, there are other causes for this condition. These include inadequate fluid consumption, sleeping with your mouth open, and weather conditions. The decreasing function of the salivary gland may or may not cause xerostomia to develop. This condition is most common in the elderly due to the frequent use of medication. It affects around 20% of the elderly worldwide. Xerostomia is associated with difficulty eating, speaking, swallowing, and wearing dentures. A dew patient suffering from this disease also suffers from dysgeusia, glossodynia, and other dental complications. To determine the function of the salivary gland, various diagnostic and imaging tests such as sialometry, salivary flow measurement, and sialography are recommended. If the salivary flow rate is less than 0.1 ml/minute, the condition is considered xerostomia.
- Increasing Adoption of Chemotherapy and Radiotherapy in Cancer Treatment
- The Rising Use of Prescribed Medications
- Rising Consumption of Medications
- Favorable Reimbursement Policies
- Growing Geriatric Population Including Aging Baby Boomers
- Easy Availability of Cost-Effective Medications
- Increasing Prevalence of Diseases Such As Parkinson’s disease, Hypertension, Diabetes, And HIV
- Scarcity of Skilled Professionals to Avail the Proper Treatment Options
- Availability of a Wide Range of Substitutes
- Growing Awareness and Supporting Patients with Xerostomia
- Growing Healthcare Expenditure and Availability of Advanced Health Care Facilities
- The Lack of Awareness among the People
The companies are now exploring the market by adopting mergers & acquisitions, expansions, investments, new developments in existing products, and collaborations as their preferred strategies. The players are also exploring new geographies and industries through expansions and acquisitions so as to avail a competitive advantage through combined synergies.
Some of the key players profiled in the report are GlaxoSmithKline (United Kingdom), Church and Dwight Co., Inc. (United States), Hikma Pharmaceuticals (United Kingdom), Pendopharm (Canada), Parnell Pharmaceuticals, Inc. (Australia), Orahealth Corporation (United States), Eisai Co., Ltd (Japan), EUSA Pharma (United Kingdom), Colgate-Palmolive Company (United States), Forward Science (United States), Mission Pharmacal Company (United States) and OraPharma, Inc. (United States). Additionally, following companies can also be profiled that are part of our coverage like Saliwell Ltd. (Israel) and Sun Pharmaceutical Industries Limited (India). Analyst at AdvanceMarketAnalytics see United States Players to retain maximum share of Global Xerostomia Treatments market by 2025. Considering Market by Treatment Type, the sub-segment i.e. Artificial Saliva will boost the Xerostomia Treatments market. Considering Market by Symptoms, the sub-segment i.e. Sjogren’s Syndrome will boost the Xerostomia Treatments market.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Xerostomia Treatments market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Xerostomia Treatments market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Providers of Xerostomia Treatments, Research Institute, Potential Investors, Hospitals Sectors, Government Sector and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.